Skip to main content

Advertisement

Table 3 Median concentrations in plasma of uPA (pg/mL), PGE2 (ng/mL) and celecoxib (ng/mL) based on celecoxib dose and menopausal status1

From: uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer

Dose N Baseline After Tx Δ P Value Celecoxib
200 mg bid 2       
uPA       
Overall 17 941.4 955.0 -20.7 0.85 233.7
Premen 4 886.9 1031.8 36.0 0.62 195.3
Postmen 13 994.0 945.6 -20.7 0.64 233.7
PGE 2       
Overall 17 0.209 0.206 0.005 0.96 233.7
Premen 4 0.244 0.221 0.100 0.99 0
Postmen 13 0.204 0.195 0.005 0.84 233.7
400 mg bid 2       
uPA       
Overall 25 908.3 910.7 17.5 0.8 696.0
Premen 11 864.9 821.0 17.5 0.8 227.3
Postmen 14 1036.1 992.4 7.9 0.7 1024.9
PGE 2       
Overall 25 0.280 0.203 -0.009 0.93 696.0
Premen 11 0.375 0.366 -0.001 0.77 227.2
Postmen 14 0.280 0.175 -0.023 0.90 1025.0
  1. 1: N: sample size; NAF: nipple aspirate fluid. Units reflect pg uPA/mL plasma volume. Δ uPA reflects the median of the change measured in each subject (after treatment value – before treatment value) due to treatment. Celecoxib level is from plasma collected after treatment.
  2. 2: bid: twice daily; premen: premenopausal; postmen: postmenopausal.